Tumour Infiltrating Lymphocytes in Follicular Lymphoma - additional data 7
收藏官方服务：
资源简介：
Part 7/10 Description provided in the dataset linked below.
下述为所链接数据集中的第7/10部分描述。
应用场景：
创建时间：
2021-01-04
相关数据集
Transcriptome analysis of tumor infiltrating NK and T cells in CT26-bearing BALB/C mice
CT26 tumors were implanted subcutaneously into syngeneic BALB/C mice and allowed to grow for 15-25 days. Tumors were collected, mechanically dissociated, and immune cells enriched using Percoll gradie
NIAID Data Ecosystem60
NR1H3 (LXRα) IS ASSOCIATED WITH PRO-INFLAMMATORY MACROPHAGES, PREDICTS SURVIVAL AND PROVIDES RATIONALE FOR NEW IMMUNOMODULATION IN DIFFUSE LARGE B-CELL LYMPHOMA
The role of macrophages (Mo) and their prognostic impact in diffuse large B-cell lymphomas (DLBCL) remain controversial. By regulating the lipid metabolism, Liver-X-receptors (LXRs) control Mo polariz
NIAID Data Ecosystem30
Spatially-resolved transcriptomics reveal macrophage heterogeneity and prognostic significance in diffuse large B-cell lymphoma. Spatially-resolved transcriptomics reveal macrophage heterogeneity and prognostic significance in diffuse large B-cell lymphoma
Macrophages are abundant immune cells in the microenvironment of diffuse large B-cell lymphoma (DLBCL). Macrophage phenotyping by immunohistochemistry has varying prognostic significance across studie
NIAID Data Ecosystem20
CD8+ TILs in NSCLC differentiate into TEMRA via a bifurcated trajectory, deciphering immunogenicity of tumor-antigens. CD8+ TILs in NSCLC differentiate into TEMRA via a bifurcated trajectory, deciphering immunogenicity of tumor-antigens
CD8+ tumor-infiltrating lymphocytes (TILs) comprise phenotypically and functionally heterogeneous subpopulations. Of these, effector memory CD45RA-expressing CD8+ T cells (Temra) have been discovered
NIAID Data Ecosystem60
Table_1_POLE and Mismatch Repair Status, Checkpoint Proteins and Tumor-Infiltrating Lymphocytes in Combination, and Tumor Differentiation: Identify Endometrial Cancers for Immunotherapy.docx
ObjectiveAlthough Polymerase-epsilon (POLE)-mutated and mismatch repair (MMR)-deficient endometrial cancers (ECs) are considered as promising candidates for anti-PD-1/PD-L1 therapy, selecting only the
NIAID Data Ecosystem30
